Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S354.
doi: 10.21037/atm.2019.09.92.

Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?

Arpit Rao  1 , Emmanuel S Antonarakis  2
Affiliations
Editorial

Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?

Arpit Rao et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: A Rao has served as a paid consultant for QED Therapeutics; has received research funding from Eli Lilly, Sanofi, Genentech, and Clovis Oncology. ES Antonarakis has served as a paid consultant/advisor for Janssen, Astellas, Sanofi and Merck; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Bristol Myers Squibb, Genentech, Novartis and Bayer; and is a co-inventor of a biomarker technology that has been licensed to Qiagen.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J 2010;4:380-4. 10.5489/cuaj.10167 - DOI - PMC - PubMed
    1. Rao A, Vapiwala N, Ryan CJ, et al. Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? In: American Society of Clinical Oncology Educational Book, 2019:309-20. Available online: https://ascopubs.org/doi/full/10.1200/EDBK_239041 10.1200/EDBK_239041 - DOI - DOI - PubMed
    1. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28. 10.1016/j.cell.2015.05.001 - DOI - PMC - PubMed
    1. Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature 2017;548:297-303. 10.1038/nature23306 - DOI - PMC - PubMed
    1. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152-60. 10.1016/S1470-2045(14)71205-7 - DOI - PubMed